Greenway Greenhouse Cannabis Corporation

FRC's fair value estimate for Greenway Greenhouse Cannabis Corporation, and the rating behind it. GWAY.CN last traded at C$0.21; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Greenway Greenhouse Cannabis Corporation. Starting points for Greenway Greenhouse Cannabis Corporation: EPS -C$0.02, beta 0.02 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Greenway Greenhouse Cannabis Corporation. Greenway Greenhouse Cannabis Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Greenway Greenhouse Cannabis Corporation. Trailing twelve-month EPS for Greenway Greenhouse Cannabis Corporation stands at -C$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Greenway Greenhouse Cannabis Corporation. Greenway Greenhouse Cannabis Corporation has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Greenway Greenhouse Cannabis Corporation valued side by side against its closest peers. Greenway Greenhouse Cannabis Corporation is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Greenway Greenhouse Cannabis Corporation, and how their positions are changing. At a C$27.8M market value, institutional positions materially move Greenway Greenhouse Cannabis Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Greenway Greenhouse Cannabis Corporation executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Greenway Greenhouse Cannabis Corporation. Greenway Greenhouse Cannabis Corporation is a C$27.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Greenway Greenhouse Cannabis Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Greenway Greenhouse Cannabis Corporation. Coverage tracks Greenway Greenhouse Cannabis Corporation within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.